Condition: Intracerebral Haemorrhage · Minimally Invasive Treatment · Sponsor: Tongji Hospital
This is an phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigational arm (stereotactic minimally invasive puncture for intracerebral hemorrhage combined with TNK liquefaction drainage, single TNK dose of 0.5mg per time or the standard medical treatment group.
This description comes directly from the study's public registry record.
Pan Chao, MD, PhD · 86-027-83663337 · ddjtzp@163.com; punctualpc@163.com
Always discuss trial participation with your own doctor first.
| Suzhou First People's Hospital | Suzhou, Anhui, China | Recruiting |
| Guizhou Medical University Affiliated Hospital | Guiyang, Guizhou, China | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07208097